Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | 1.32% | 697.33 | 2.6% | $644.85m | |
| MRNA | Moderna, Inc. | -0.55% | 123.64 | 0.0% | $634.51m | |
| AMGN | Amgen, Inc. | -0.34% | 226.97 | 1.4% | $624.69m | |
| GILD | Gilead Sciences, Inc. | -1.43% | 62.86 | 1.0% | $494.49m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.01% | 283.45 | 1.9% | $355.83m | |
| ILMN | Illumina, Inc. | -1.61% | 190.38 | 3.2% | $291.37m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -5.81% | 4.05 | 0.7% | $283.11m | |
| BIIB | Biogen, Inc. | -1.42% | 197.78 | 1.8% | $184.42m | |
| SAVA | Cassava Sciences, Inc. | -18.00% | 41.87 | 0.0% | $173.71m | |
| BNTX | BioNTech SE | -1.27% | 128.35 | 0.0% | $100.39m | |
| NRBO | NeuroBo Pharmaceuticals, Inc. | -6.44% | 15.54 | 0.0% | $89.03m | |
| NVAX | Novavax, Inc. | -6.42% | 21.00 | 75.6% | $85.66m | |
| BMRN | BioMarin Pharmaceutical, Inc. | -0.09% | 84.84 | 4.2% | $76.07m | |
| EXAS | EXACT Sciences Corp. | -2.74% | 33.41 | 17.6% | $71.49m | |
| CRSP | CRISPR Therapeutics AG | -2.68% | 63.16 | 0.6% | $69.53m |
Company Profile
Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.